324 related articles for article (PubMed ID: 32321511)
1. Recent advances in human iPSC-derived models of the blood-brain barrier.
Workman MJ; Svendsen CN
Fluids Barriers CNS; 2020 Apr; 17(1):30. PubMed ID: 32321511
[TBL] [Abstract][Full Text] [Related]
2. Human iPSC-Derived Blood-Brain Barrier Chips Enable Disease Modeling and Personalized Medicine Applications.
Vatine GD; Barrile R; Workman MJ; Sances S; Barriga BK; Rahnama M; Barthakur S; Kasendra M; Lucchesi C; Kerns J; Wen N; Spivia WR; Chen Z; Van Eyk J; Svendsen CN
Cell Stem Cell; 2019 Jun; 24(6):995-1005.e6. PubMed ID: 31173718
[TBL] [Abstract][Full Text] [Related]
3. Barrier Properties and Transcriptome Expression in Human iPSC-Derived Models of the Blood-Brain Barrier.
Delsing L; Dönnes P; Sánchez J; Clausen M; Voulgaris D; Falk A; Herland A; Brolén G; Zetterberg H; Hicks R; Synnergren J
Stem Cells; 2018 Dec; 36(12):1816-1827. PubMed ID: 30171748
[TBL] [Abstract][Full Text] [Related]
4. An isogenic blood-brain barrier model comprising brain endothelial cells, astrocytes, and neurons derived from human induced pluripotent stem cells.
Canfield SG; Stebbins MJ; Morales BS; Asai SW; Vatine GD; Svendsen CN; Palecek SP; Shusta EV
J Neurochem; 2017 Mar; 140(6):874-888. PubMed ID: 27935037
[TBL] [Abstract][Full Text] [Related]
5. Recent progress and new challenges in modeling of human pluripotent stem cell-derived blood-brain barrier.
Yan L; Moriarty RA; Stroka KM
Theranostics; 2021; 11(20):10148-10170. PubMed ID: 34815809
[TBL] [Abstract][Full Text] [Related]
6. Generation of a Human iPSC-Based Blood-Brain Barrier Chip.
Jagadeesan S; Workman MJ; Herland A; Svendsen CN; Vatine GD
J Vis Exp; 2020 Mar; (157):. PubMed ID: 32176199
[TBL] [Abstract][Full Text] [Related]
7. Cryopreservation of Brain Endothelial Cells Derived from Human Induced Pluripotent Stem Cells Is Enhanced by Rho-Associated Coiled Coil-Containing Kinase Inhibition.
Wilson HK; Faubion MG; Hjortness MK; Palecek SP; Shusta EV
Tissue Eng Part C Methods; 2016 Dec; 22(12):1085-1094. PubMed ID: 27846787
[TBL] [Abstract][Full Text] [Related]
8. Models of the blood-brain barrier using iPSC-derived cells.
Delsing L; Herland A; Falk A; Hicks R; Synnergren J; Zetterberg H
Mol Cell Neurosci; 2020 Sep; 107():103533. PubMed ID: 32717317
[TBL] [Abstract][Full Text] [Related]
9. Blood-Brain Barrier and Neurodegenerative Diseases-Modeling with iPSC-Derived Brain Cells.
Wu YC; Sonninen TM; Peltonen S; Koistinaho J; Lehtonen Š
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299328
[TBL] [Abstract][Full Text] [Related]
10. Isogenic blood-brain barrier models based on patient-derived stem cells display inter-individual differences in cell maturation and functionality.
Patel R; Page S; Al-Ahmad AJ
J Neurochem; 2017 Jul; 142(1):74-88. PubMed ID: 28397247
[TBL] [Abstract][Full Text] [Related]
11. Activation of RARα, RARγ, or RXRα Increases Barrier Tightness in Human Induced Pluripotent Stem Cell-Derived Brain Endothelial Cells.
Stebbins MJ; Lippmann ES; Faubion MG; Daneman R; Palecek SP; Shusta EV
Biotechnol J; 2018 Feb; 13(2):. PubMed ID: 28960887
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Drug Permeability Using
Ohshima M; Kamei S; Fushimi H; Mima S; Yamada T; Yamamoto T
Biores Open Access; 2019; 8(1):200-209. PubMed ID: 31737437
[TBL] [Abstract][Full Text] [Related]
13. Challenges and opportunities in the use of transcriptomic characterization of human iPSC-derived BBB models.
Wellens S; Gosselet F; Culot M
Toxicol In Vitro; 2022 Oct; 84():105424. PubMed ID: 35760296
[TBL] [Abstract][Full Text] [Related]
14. Accelerated differentiation of human induced pluripotent stem cells to blood-brain barrier endothelial cells.
Hollmann EK; Bailey AK; Potharazu AV; Neely MD; Bowman AB; Lippmann ES
Fluids Barriers CNS; 2017 Apr; 14(1):9. PubMed ID: 28407791
[TBL] [Abstract][Full Text] [Related]
15. Proof-of-Concept Study of Drug Brain Permeability Between in Vivo Human Brain and an in Vitro iPSCs-Human Blood-Brain Barrier Model.
Roux GL; Jarray R; Guyot AC; Pavoni S; Costa N; Théodoro F; Nassor F; Pruvost A; Tournier N; Kiyan Y; Langer O; Yates F; Deslys JP; Mabondzo A
Sci Rep; 2019 Nov; 9(1):16310. PubMed ID: 31690750
[TBL] [Abstract][Full Text] [Related]
16. Modeling Group B
Kim BJ; Bee OB; McDonagh MA; Stebbins MJ; Palecek SP; Doran KS; Shusta EV
mSphere; 2017; 2(6):. PubMed ID: 29104935
[TBL] [Abstract][Full Text] [Related]
17. Studying Human Neurological Disorders Using Induced Pluripotent Stem Cells: From 2D Monolayer to 3D Organoid and Blood Brain Barrier Models.
Logan S; Arzua T; Canfield SG; Seminary ER; Sison SL; Ebert AD; Bai X
Compr Physiol; 2019 Mar; 9(2):565-611. PubMed ID: 30873582
[TBL] [Abstract][Full Text] [Related]
18. Neurological diseases at the blood-brain barrier: Stemming new scientific paradigms using patient-derived induced pluripotent cells.
Page S; Patel R; Raut S; Al-Ahmad A
Biochim Biophys Acta Mol Basis Dis; 2020 Apr; 1866(4):165358. PubMed ID: 30593893
[TBL] [Abstract][Full Text] [Related]
19. Microfluidic blood-brain barrier model provides in vivo-like barrier properties for drug permeability screening.
Wang YI; Abaci HE; Shuler ML
Biotechnol Bioeng; 2017 Jan; 114(1):184-194. PubMed ID: 27399645
[TBL] [Abstract][Full Text] [Related]
20. The role of mutations associated with familial neurodegenerative disorders on blood-brain barrier function in an iPSC model.
Katt ME; Mayo LN; Ellis SE; Mahairaki V; Rothstein JD; Cheng L; Searson PC
Fluids Barriers CNS; 2019 Jul; 16(1):20. PubMed ID: 31303172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
